该公司的分析表明，Alkermes的股价目前已经考虑了即期挑战，同时也计入了其开发中治疗药物的潜在收入。RBC Capital Markets的立场表明，他们正在密切关注更多数据，以进一步评估该药物在竞争市场中的前景以及公司的整体财务健康状况。 InvestingPro ...

2025年3月12日周三，Alkermes Plc（NASDAQ: ALKS）在2025年Leerink全球医疗大会上发表演讲，重点介绍了其Orexin管线和强劲商业产品的战略重点。公司在竞争压力下强调了其神经科学领域的重点和增长战略，同时阐述了机遇与挑战。

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...

More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has entered a license, supply and commercialization agreement with ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...